… ProQR Receives Fast Track Designation from the FDA for QR-110 … for Leber’s Congenital Amaurosis Type 10 Key Updates ProQR receives Fast Track designation by the U.S. Food and … which there is currently nothing available,” said Noreen R. Henig, Chief Medical Officer of ProQR. “We are also …
… ProQR Announces Closing of Initial Public Offering and Full … The Netherlands, Sept. 23, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) announced today the … securities laws of any such state or jurisdiction. About ProQR We are an innovative biopharmaceutical company engaged …
… ProQR Announces Positive Top-Line Results from the Phase 1/2 … Retinal Disease community as a whole,” said Stephen R. Russell, MD, Schrage Professor of Ophthalmology and Visual … Executive Vice President of Research & Development of ProQR, said, “We are very pleased with the data reported from …
… ProQR Therapeutics Announces $8.1 Million in New Funding from … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … who have the R270X mutation in MECP2 gene, and is based on ProQR’s proprietary Axiomer RNA editing platform. Axiomer can …
… ProQR Announces Positive Top-Line Results from a Phase 1b … improvement of CF respiratory symptoms, as measured by CFQ-R RSS, was observed in 3 out of 4 multiple dose groups with a … said Noreen R. Henig, M.D, Chief Medical Officer at ProQR. “I want to thank the entire CF community including …
… ProQR to Present its Axiomer® RNA Editing Technology at the … & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … USA, that is being held May 9-12, 2022 in Boston, MA, U.S. ProQR presentation Presentation title: Development of RNA …
… ProQR Announces Top-Line Results from Phase 2/3 Illuminate … Daniel A. de Boer, Founder and CEO of ProQR Therapeutics. “ProQR was founded with the goal of developing RNA therapies … many are feeling in the community,” said Benjamin R. Yerxa, Chief Executive Officer at the Foundation Fighting …
… ProQR Announces First Patients Dosed in Phase 2/3 Pivotal … & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … testing,” said Aniz Girach, M.D., Chief Medical Officer of ProQR. “In a previous clinical study, QR-421a appeared to be …